$Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting$

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior ther...

Bibliografske podrobnosti
Main Authors:	Eyre, T, Phillips, E, Linton, K, Kassam, S, Gibb, A, Allibone, S, Radford, J, Peggs, K, Burton, C, Stewart, G, LeDieu, R, Booth, C, Osborne, W, Miall, F, Eyre, D, Ardeshna, K, Collins, G
Format:	Journal article
Jezik:	English
Izdano:	Wiley 2017

Podobne knjige/članki

Brentuximab vedotin in pediatric Hodgkin lymphoma
od: Shuvadeep Ganguly, et al.
Izdano: (2022-01-01)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
od: Illidge T, et al.
Izdano: (2012-05-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
od: G. S. Tumyan
Izdano: (2018-11-01)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
od: Hung-Bo Wu, et al.
Izdano: (2013-01-01)

Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
od: Shuvadeep Ganguly, et al.
Izdano: (2022-01-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
od: Chen R, et al.
Izdano: (2015-03-01)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
od: Lai C, et al.
Izdano: (2019-12-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
od: Siddiqi T, et al.
Izdano: (2014-02-01)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
od: Ayana Uchimura, et al.
Izdano: (2022-03-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
od: Michelle Furtado, et al.
Izdano: (2012-01-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
od: G. R. Khachatryan, et al.
Izdano: (2016-04-01)

Brentuximab vedotin induced uveitis
od: Stijn Therssen, M.D., et al.
Izdano: (2022-06-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
od: N. A. Avxentyev, et al.
Izdano: (2020-12-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
od: E. A. Demina
Izdano: (2017-11-01)

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
od: Rebecca L. Allchin, et al.
Izdano: (2020-12-01)

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
od: Adrian Schmidt
Izdano: (2020-11-01)

Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
od: Mehdi Hamadani
Izdano: (2021-12-01)

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
od: Dayeeta Bera, et al.
Izdano: (2024-02-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
od: Aimee Schad, et al.
Izdano: (2023-09-01)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
od: A. J. N. Raymakers, et al.
Izdano: (2020-10-01)

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
od: Feng-Ming Tien, et al.
Izdano: (2019-10-01)

Assessment of the efficiency of Brentuximab Vedotin in patients with pulmonary Hodgkin Lymphoma by the mean of neutrophil to lymphocyte ratio
od: Gokhan Erdem, et al.
Izdano: (2018-04-01)

T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
od: Sharon M. Castellino, et al.
Izdano: (2022-10-01)

Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion
od: Ellen Marin, et al.
Izdano: (2025-02-01)

Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy
od: Chiara Bini, et al.
Izdano: (2024-12-01)

Insights into uveitis from Brentuximab vedotin in refractory Hodgkin’s lymphoma: a case report and brief review
od: Mengyuan Liu, et al.
Izdano: (2024-08-01)

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
od: Shitong Xie, et al.
Izdano: (2024-06-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
od: Ruizhi Zhao, et al.
Izdano: (2024-03-01)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
od: Matthew Mei, et al.
Izdano: (2022-10-01)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
od: Swetha Kambhampati, et al.
Izdano: (2022-10-01)

A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin
od: Federico Meconi, et al.
Izdano: (2020-08-01)

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
od: Adam Gibb, et al.
Izdano: (2013-04-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
od: N. V. Myakova, et al.
Izdano: (2016-03-01)

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
od: Howland E. Crosswell, et al.
Izdano: (2023-10-01)

Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature
od: Keiki Nagaharu, et al.
Izdano: (2018-05-01)

Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy
od: Wilbur Montana, et al.
Izdano: (2017-09-01)

Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect
od: Roberta Pece, et al.
Izdano: (2021-06-01)

P017 (0120) IMMUNOLOGIC BIOMARKERS OF RESPONSE AND RESISTANCE TO BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Izdano: (2018-10-01)

P110 (0014) SUCCESSFUL TREATMENT OF HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Izdano: (2018-10-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
od: Kana Nagashima, et al.
Izdano: (2020-03-01)